Seres Therapeutics (NASDAQ:MCRB - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday.
Several other equities research analysts have also recently issued reports on MCRB. Canaccord Genuity Group reiterated a "buy" rating and issued a $22.00 price objective on shares of Seres Therapeutics in a report on Friday, March 13th. Weiss Ratings reiterated a "sell (d)" rating on shares of Seres Therapeutics in a report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Seres Therapeutics currently has a consensus rating of "Hold" and an average price target of $22.00.
Get Our Latest Report on MCRB
Seres Therapeutics Stock Down 0.3%
Shares of Seres Therapeutics stock opened at $7.70 on Friday. Seres Therapeutics has a twelve month low of $6.53 and a twelve month high of $29.98. The business has a 50-day moving average price of $8.65 and a 200 day moving average price of $13.05. The firm has a market cap of $74.54 million, a PE ratio of -1.49 and a beta of 0.12.
Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The company had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.36 million.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. boosted its holdings in shares of Seres Therapeutics by 37.5% during the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company's stock worth $214,000 after purchasing an additional 3,918 shares during the last quarter. 683 Capital Management LLC acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $778,000. ExodusPoint Capital Management LP acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $190,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Seres Therapeutics during the 4th quarter worth approximately $214,000. Finally, Barclays PLC boosted its holdings in shares of Seres Therapeutics by 427.8% during the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company's stock worth $111,000 after purchasing an additional 6,024 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.
Seres Therapeutics Company Profile
(
Get Free Report)
Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company's approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.
Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
